Stocks Health care BBOT
NASDAQ · Health careBridgeBio Oncology Therapeutics, Inc. (BBOT)
It posted a net loss of $182.1M. In fiscal 2025 capital spending exceeded operating cash flow by $114.5M. At June 30, 2026 it held $54.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about BridgeBio Oncology Therapeutics, Inc.
- Net worth
- BridgeBio Oncology Therapeutics, Inc. has a market value (market cap) of $184.4M at the latest share price, and shareholders' equity of $323.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $113.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- BridgeBio Oncology Therapeutics, Inc.'s next report was expected around November 10, 2026 and is not on file with the SEC yet.
What BridgeBio Oncology Therapeutics, Inc. does
BridgeBio Oncology Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BBOT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$134M | -$4.30 | -$114.5M |
| 2024 | n/a | -$74.3M | -$5,756.41 | -$55.1M |
| 2024 | n/a | -$41.7K | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What BridgeBio Oncology Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- September 8, 2026Other event 8-K
- September 1, 2026
- September 1, 2026Form POS AM filing POS AM
- August 11, 2026
- August 11, 2026
- July 6, 2026Activist stake changed SCHEDULE 13D/A
- June 22, 2026
- May 12, 2026
- May 12, 2026
Insider trades
What the people running BridgeBio Oncology Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 7 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 21, 2026 | Cobo MarcPrincipal Accounting Officer | Shares withheld for tax | 203 | $544 |
| October 1, 2026 | Ben YongChief Med & Dev Officer | Shares withheld for tax | 1,047 | $4.1K |
| October 1, 2026 | Beltran PedroPresident and CEO, Director | Shares withheld for tax | 1,047 | $4.1K |
| October 1, 2026 | Elmelech IdanCOO & Principal Financial Ofcr | Shares withheld for tax | 343 | $1.4K |
| October 1, 2026 | Cobo MarcPrincipal Accounting Officer | Shares withheld for tax | 126 | $496.4 |
| September 10, 2026 | Cobo MarcPrincipal Accounting Officer | Received as pay | 9,038 | - |
| September 10, 2026 | Cobo MarcPrincipal Accounting Officer | Shares withheld for tax | 203 | $1.1K |
| July 1, 2026 | Beltran PedroPresident and CEO, Director | Shares withheld for tax | 1,047 | $8.2K |
Who owns BBOT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bihua Chen13D, may seek influence with 7 related filers | 22.32% | July 6, 2026 |
| BridgeBio Pharma LLC13D, may seek influence with 1 related filers | 17.5% | August 18, 2025 |
| BlackRock Portfolio Management LLC13G, passive | 7.9% | April 15, 2025 |
| Deerfield Management Company, L.P.13G, passive with 5 related filers | 6.17% | August 18, 2025 |
| BC Global Opportunities IX LP13G, passive with 3 related filers | 5.5% | September 3, 2025 |
| Sculptor Capital LP13G, passive with 6 related filers | 5.12% | July 24, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 66 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Cormorant Asset Management, LP | 17,878,594 | 0 |
| Deerfield Management Company, L.P. | 4,885,446 | 0 |
| Omega Fund Management, LLC | 3,289,661 | 0 |
| EcoR1 Capital, LLC | 2,823,126 | 0 |
| Alphabet Inc. | 2,823,126 | 0 |
| Wellington Management Group Llp | 2,789,302 | -29,046 |
| Enavate Sciences GP, LLC | 2,626,946 | 0 |
| Citadel Advisors LLC | 2,617,827 | +89,065 |
| Novo Holdings A/S | 2,250,000 | +64,077 |
| BlackRock, Inc. | 2,154,040 | +65,743 |
| Vanguard Capital Management LLC | 2,005,649 | +1,467,208 |
| Laurion Capital Management LP | 2,002,701 | +80,045 |
| Armistice Capital, LLC | 1,764,000 | +436,000 |
| State Street Corp | 1,036,569 | +810,291 |
| Aisling Capital Management LP | 1,018,018 | 0 |
| Opaleye Management Inc. | 700,000 | +646,718 |
| Geode Capital Management, LLC | 622,351 | +43,117 |
| Granahan Investment Management, LLC | 558,526 | +327,486 |
| Sphera Funds Management Ltd. | 460,985 | new |
| Adage Capital Partners GP, L.L.C. | 400,000 | 0 |
Insiders
6 insiders reported holding 6,221,049 shares in total, about $14.3M at the last price.
| Holder | Shares |
|---|---|
| Chen BihuaDirector, 10% owner | 6,083,2216,083,221 held indirectly |
| Ben YongChief Med & Dev Officer | 43,529 |
| Beltran PedroPresident and CEO, Director | 43,529 |
| Mehra UneekFormer Officer | 22,806 |
| Elmelech IdanCOO & Principal Financial Ofcr | 14,152 |
| Cobo MarcPrincipal Accounting Officer | 13,812 |
Questions about BBOT
What does BridgeBio Oncology Therapeutics, Inc. do?
BridgeBio Oncology Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as BBOT. Its shares trade on NASDAQ under the ticker BBOT.
What is BridgeBio Oncology Therapeutics, Inc.'s net worth?
BridgeBio Oncology Therapeutics, Inc. has a market value (market cap) of $184.4M at the latest share price, and shareholders' equity of $323.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is BridgeBio Oncology Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $182.1M.
When did BridgeBio Oncology Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from November 5, 2026.
When is BridgeBio Oncology Therapeutics, Inc.'s next earnings report?
BridgeBio Oncology Therapeutics, Inc.'s next report was expected around November 10, 2026 and is not on file with the SEC yet.
Similar companies
Compare BBOT with
Follow BBOT
Get an email when BridgeBio Oncology Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BridgeBio Oncology Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.